title: Clinical potential of GABAB receptor modulators.
abstract: Metabotropic gamma-aminobutyric acid(B) (GABAB) receptors for the major inhibitory transmitter GABA, together with metabotropic glutamate (mGLuRs) receptors, the extracellular calcium-sensing receptors (CaSRs), some V2R pheromone receptors and T1R taste receptors, belong to the family of 3 G-protein-coupled receptors (GPCRs). GABAB receptors are known to control neuronal excitability and modulate synaptic neurotransmission, playing a very important role in many physiological activities. These receptors are widely expressed and distributed in the nervous system and have been implicated in a variety of neurodegenerative and pathophysiological disorders including epilepsy, spasticity, chronic pain, depression, schizophrenia and drug addiction. To form a functional receptor entity, GABAB receptors must exist as a heterodimer consisting of GABAB1 and GABAB2 receptor subtypes with two 7-transmembrane proteins, and these subunits arise from distinct genes. The GABAB1 subunit binds the endogenous ligand within its extracellular N-terminus, whilst the GABAB2 subunit is not only essential for the correct trafficking of the GABAB1 subunit to the cell surface, but is also responsible for the interaction of the receptor with its cognate G-protein. Allosteric modulation has recently been recognized as an alternative pharmacological approach to gain selectivity in drug action. It is now generally accepted that modulators acting at the allosteric sites provide a novel perspective for the development of subtype-selective agents acting at GPCRs. These agents interact with allosteric binding sites quite separate from the highly conserved agonist binding region. In this review, we present a new class of phenylalkylamines, based on the lead compound fendiline, that are potent positive potentiators of GABAB receptor-mediated function and discuss their putative clinical applications. It is proposed that these new modulators may have therapeutic value in GABAB receptor pharmacology and are capable of selectively modifying GABAB receptor function. The allosteric modulators are offering an attractive and novel means to identify new leads, that are devoid of side effects associated with GABAB receptor agonists, and may, therefore, represent a major advance in the drug discovery process.
authors.affiliation: Department of Anaesthesia and Intensive Care, The University of Adelaide, Australia. jennifer.ong@adelaide.edu.au
authors.forename: Jennifer
authors.initials: J
authors.lastname: Ong
authors.forename: David I B
authors.initials: DI
authors.lastname: Kerr
mesh_terms: D000818:Animals; D001007:Anxiety / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D018757:GABA Modulators / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018080:Receptors, GABA-B / Q000187:drug effects*; D019966:Substance-Related Disorders / Q000188:drug therapy
chemical_list: D018757:GABA Modulators; D018080:Receptors, GABA-B